One‐year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Aim: Assess long‐term safety and efficacy of the dipeptidlyl peptidase-4 (DPP ‐4) inhibitor vildagliptin in 369 patients with type 2 diabetes mellitus ( T2DM ) and moderate or severe renal impairment ( RI ). Methods: Double‐blind, randomized, parallel‐group, 52‐week clinical trial comparing safety and efficacy of vildagliptin (50 mg qd, n = 216) and placebo (n = 153) added to ongoing stable antihyperglycaemic treatment, in patients with T2DM and moderate or severe (glomerular filtration rate [ GFR ] ≥30 to <50 ml/min/1.73 m 2 and < 30 ml/min/1.73 m 2 ) RI . Results: The study population comprised 122 and 89 patients with moderate RI and 94 and 64 patients with severe RI randomized to vildagliptin and placebo, respectively, with the majority of patients receiving background insulin therapy (72% and 82% for moderate and severe RI , respectively). After 1 year, the between‐treatment difference in adjusted mean change in A1C was −0.4 ± 0.2% (p = 0.005) in moderate RI (baseline = 7.8%) and −0.7 ± 0.2% (p < 0.0001) in severe RI (baseline = 7.6%). In patients with moderate RI , similar proportions of patients experienced any adverse event ( AE ) (84 vs. 85%), any serious adverse event ( SAE ) (21 vs. 19%), any AE leading to discontinuation (5% vs. 6%) and death (1% vs. 0%) with vildagliptin and placebo, respectively. This was also true for patients with severe RI : AEs (85% vs. 88%), SAEs (25% vs. 25%), AEs leading to discontinuation (10% vs. 6%) and death (3% vs. 2%). Conclusions: In patients with T2DM and moderate or severe RI , vildagliptin added to ongoing antidiabetic therapy had a safety profile similar to placebo during 1‐year observation. Furthermore, relative to placebo, a clinically significant decrease in A1C was maintained throughout 1‐year treatment with vildagliptin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Risk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration
UK Hypoglycaemia Study Group (2007) · Diabetologia · doi:10.1007/s00125-007-0599-y · Cited by 825
Glucose-Dependent Insulinotropic Polypeptide
Christensen, M., Vedtofte, L., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2011) · Diabetes · doi:10.2337/db11-0979 · Cited by 353
Insulin Glulisine Provides Improved Glycemic Control in Patients With Type 2 Diabetes
Dailey, G., Rosenstock, J., Moses, R. G., & Ways, K. (2004) · Diabetes Care · doi:10.2337/diacare.27.10.2363 · Cited by 153 · cited 1×
“6%) receiving insulin±OADs [15,16].”
Cited by
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
“Several studies have demonstrated that the glucose-lowering efficacy is maintained while a good safety profile when reduced doses of these gliptins are utilized in patients with renal impairment [306-309] .”
BackgroundLi, L., Shen, J., Bala, M. M., Busse, J. W., Ebrahim, S., Vandvik, P. O., Rios, L. P., Malaga, G., Wong, E., Sohani, Z., et al. (2014) · BMJ · doi:10.1136/bmj.g2366 · Cited by 254
Haidinger, M., Werzowa, J., Hecking, M., Antlanger, M., Stemer, G., Pleiner, J., Kopecky, C., Kovarik, J. J., Döller, D., Pacini, G., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12518 · Cited by 110
“DPP-4 inhibitors can be used even for patients on hemodialysis, and have been shown to preserve pancreatic beta cell function in animal models of diabetes (7,38,39).”
BackgroundScheen, A. J. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0198-2 · Cited by 102
Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease
Scheen, A. J. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.777428 · Cited by 91
Metadata
- Authors
- Kothny, W., Shao, Q., Groop, P. ‐., & Lukashevich, V.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2012-07-08
- Volume
- 14
- Issue
- 11
- Pages
- 1032-1039
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2154277743
- Cited by
- 104
- References
- 4
- FWCI
- 12.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: One‐year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. https://app.cochat.ai/papers/10.1111/j.1463-1326.2012.01634.x
- The paper
- Kothny, W., Shao, Q., Groop, P. ‐., & Lukashevich, V. (2012). One‐year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2012.01634.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.